EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PCSK6 ablation in blood circulating cells increases atherosclerotic burden, but improves plaque stability by activating Th17-smooth muscle cell modulatory axis

Bianca E Suur, Glykeria Karadimou, Colin J J M Willems, Otto Bergman, Mariette Lengquist, Malin Kronqvist, Roland Baumgartner, Stephen Malin, Anton Gisterå, Göran K Hansson, Anders Mälarstig, Ulf Hedin und 2 weitere

Vascular Pharmacology · 2025-06 · 159 · 107490

DOI: 10.1016/j.vph.2025.107490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular Pharmacology, 2025-06. Verfasst von Bianca E Suur und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Sweden; Steno Diabetes Center Aarhus, Aarhus …. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Atherosclerosis, Th17 Cells, Myocytes, Smooth Muscle. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heart and Lung Foundation, Svenska Sällskapet för Medicinsk Forskning, Vetenskapsrådet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Proprotein convertase subtilisins/kexins (PCSKs) have been implicated in cancers and cardiovascular disease. We have shown that PCSK6 is a key protease regulating smooth muscle cell (SMC)-mediated vascular remodeling, but also that it can be expressed by T cells and macrophages in atherosclerotic plaques. Whether PCSK6 regulates innate and adaptive immune responses in the context of vascular inflammation is still unknown. METHODS: In this study, detailed immunophenotyping of constitutive Pcsk6-/- mice was performed. Bone marrow transplantation into high-cholesterol diet fed Ldlr-/- mice was used to investigate PCSK6-mediated immune effects in atherogenesis and plaque stability. RESULTS: Compared to controls, Pcsk6-/- mice showed higher plasma levels of the chemoattractants CCL2 and CCCL3, and Th17 cytokines IL-17 A and IL-17F. Pcsk6 ablation led to increased naïve and effector-memory CD4+ and CD8+ cell numbers in the spleen, and increased release of IL-17 A, IFN-γ and IL-10 as well as proliferation by spleenocytes in vitro. Lack of Pcsk6 also affected innate immunity as macrophages from Pcsk6-/- mice secreted more cytokines, including TNF-α, CCL2, IL-6 and IL-10 upon LPS stimulation in vitro, and were more prone to oxLDL uptake. In line with a pro-inflammatory phenotype, Pcsk6-/-➔Ldlr-/- transplanted mice presented a higher atherosclerotic plaque burden compared to Ldlr-/- receiving control bone marrow. Although larger, Pcsk6-/-➔Ldlr-/- plaques showed increased stability features, including collagen deposition and SMC presence coinciding with significantly increased local levels of the fibrogenic cytokine IL-17. CONCLUSIONS: Global Pcsk6 ablation leads to the activation of both adaptive and innate immune systems. Interestingly, Pcsk6-/- ablation in bone marrow of hyperlipidemic mice revealed its dual role in atherogenesis, activating a Th17-SMC modulatory axis that promotes plaque stability, despite increased atherosclerotic burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plaque, AtheroscleroticAtherosclerosisTh17 CellsMyocytes, Smooth MuscleAortic DiseasesMuscle, Smooth, VascularAortaSerine EndopeptidasesAnimalsMice, KnockoutDisease Models, AnimalMice, Inbred C57BLImmunity, InnateCytokinesMaleReceptors, LDLSignal TransductionCells, CulturedAdaptive ImmunityMacrophagesMiceInflammation Mediators

Stichwörter der Autor:innen

AtherosclerosisIL-17PCSK6PlaquesSmooth muscle cellsTh17 cells

Substanzen

CytokinesReceptors, LDLSerine EndopeptidasesInflammation Mediators

Autor:innen und Institutionen

  • Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Sweden; Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark; Department of Biomedicine, Aarhu…
  • Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Sweden; Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Sweden.
  • Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Sweden.
  • Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Sweden; Department of Molecular Medicine, University of Southern Denmark, Denmark.
  • Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Sweden. Electronic address: Ljubica.Matic@ki.se.

Förderung

  • Heart and Lung Foundation
  • Svenska Sällskapet för Medicinsk Forskning
  • Vetenskapsrådet
  • Karolinska Institutet
  • Syddansk Universitet
  • Novo Nordisk Fonden
  • Henry Luce Foundation

Zitieren

APA

Suur, B. E., Karadimou, G., Willems, C. J. J. M., Bergman, O., Lengquist, M., Kronqvist, M., Baumgartner, R., Malin, S., Gisterå, A., Hansson, G. K., Mälarstig, A., Hedin, U., Ketelhuth, D. F. J., & Matic, L. (2025). PCSK6 ablation in blood circulating cells increases atherosclerotic burden, but improves plaque stability by activating Th17-smooth muscle cell modulatory axis. Vascular Pharmacology, 159, 107490. https://doi.org/10.1016/j.vph.2025.107490

Vancouver

Suur BE, Karadimou G, Willems CJJM, Bergman O, Lengquist M, Kronqvist M, et al. PCSK6 ablation in blood circulating cells increases atherosclerotic burden, but improves plaque stability by activating Th17-smooth muscle cell modulatory axis. Vascular Pharmacology. 2025;159:107490. doi:10.1016/j.vph.2025.107490

BibTeX
@article{Suur2025,
  author = {Suur, Bianca E and Karadimou, Glykeria and Willems, Colin J J M and Bergman, Otto and Lengquist, Mariette and Kronqvist, Malin and Baumgartner, Roland and Malin, Stephen and Gisterå, Anton and Hansson, Göran K and Mälarstig, Anders and Hedin, Ulf and Ketelhuth, Daniel F J and Matic, Ljubica},
  title = {PCSK6 ablation in blood circulating cells increases atherosclerotic burden, but improves plaque stability by activating Th17-smooth muscle cell modulatory axis},
  journal = {Vascular Pharmacology},
  year = {2025},
  volume = {159},
  pages = {107490},
  doi = {10.1016/j.vph.2025.107490}
}
Kostenlos starten →